Researcher profile

Qian Niu

Qian Niu contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 17 - UnverifiedVerification L1Unclaimed author
4works
0followers
8topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

4 published item(s)

preprint2026arXiv

BrainAnytime: Anatomy-Aware Cross-Modal Pretraining for Brain Image Analysis with Arbitrary Modality Availability

Clinical diagnostic workups typically follow a modality escalation pathway: after initial clinical evaluation, clinicians begin with routine structural imaging (e.g., MRI), selectively add sequences such as FLAIR or T2 to refine the differential, and reserve molecular imaging (e.g., amyloid-PET) for cases that remain uncertain after standard evaluation. Consequently, patients are observed with heterogeneous and often incomplete modality subsets. However, most current AI models assume fixed data modalities as the model inputs. In this paper, we present BrainAnytime, a unified pretraining framework pretrained on 34,899 3D brain scans from five datasets that support brain image analysis under arbitrary modality availability spanning multi-sequence MRI and amyloid-PET. A single model accepts whatever imaging is available, from a lone T1 scan to a full multimodal workup. Pretraining learns structural-molecular correspondences between MRI and PET via cross-modal distillation (RCMD) and prioritizes disease-vulnerable anatomy via atlas-guided curriculum masking (PACM), all within a shared 3D masked autoencoder (Multi-MAE3D). Across four downstream tasks and five clinically motivated modality settings, BrainAnytime largely outperforms modality-specific models, missing-modality baselines, and large-scale brain MRI pretrained foundation models on most modality settings. Notably, it surpasses the strongest missing-modality baselines with relative improvements of 6.2% and 7.0% in average accuracy on CN vs. AD and CN vs. MCI classification, respectively. Code is available at https://github.com/SDH-Lab/BrainAnytime.

preprint2026arXiv

From Bench to Bedside: A Review of Clinical Trials in Drug Discovery and Development

Clinical trials are an indispensable part of the drug development process, bridging the gap between basic research and clinical application. During the development of new drugs, clinical trials are used not only to evaluate the safety and efficacy of the drug but also to explore its dosage, treatment regimens, and potential side effects. This review discusses the various stages of clinical trials, including Phase I (safety assessment), Phase II (preliminary efficacy evaluation), Phase III (large-scale validation), and Phase IV (post-marketing surveillance), highlighting the characteristics of each phase and their interrelationships. Additionally, the paper addresses the major challenges encountered in clinical trials, such as ethical issues, subject recruitment difficulties, diversity and representativeness concerns, and proposes strategies for overcoming these challenges. With the advancement of technology, innovative technologies such as artificial intelligence, big data, and digitalization are gradually transforming clinical trial design and implementation, improving trial efficiency and data quality. The article also looks forward to the future of clinical trials, particularly the impact of emerging therapies such as gene therapy and immunotherapy on trial design, as well as the importance of regulatory reforms and global collaboration. In conclusion, the core role of clinical trials in drug development will continue to drive the progress of innovative drug development and clinical treatment.

preprint2026arXiv

From In Silico to In Vitro: A Comprehensive Guide to Validating Bioinformatics Findings

The integration of bioinformatics predictions and experimental validation plays a pivotal role in advancing biological research, from understanding molecular mechanisms to developing therapeutic strategies. Bioinformatics tools and methods offer powerful means for predicting gene functions, protein interactions, and regulatory networks, but these predictions must be validated through experimental approaches to ensure their biological relevance. This review explores the various methods and technologies used for experimental validation, including gene expression analysis, protein-protein interaction verification, and pathway validation. We also discuss the challenges involved in translating computational predictions to experimental settings and highlight the importance of collaboration between bioinformatics and experimental research. Finally, emerging technologies, such as CRISPR gene editing, next-generation sequencing, and artificial intelligence, are shaping the future of bioinformatics validation and driving more accurate and efficient biological discoveries.

preprint2025arXiv

Japanese AI Agent System on Human Papillomavirus Vaccination: System Design

Human papillomavirus (HPV) vaccine hesitancy poses significant public health challenges, particularly in Japan where proactive vaccination recommendations were suspended from 2013 to 2021. The resulting information gap is exacerbated by misinformation on social media, and traditional ways cannot simultaneously address individual queries while monitoring population-level discourse. This study aimed to develop a dual-purpose AI agent system that provides verified HPV vaccine information through a conversational interface while generating analytical reports for medical institutions based on user interactions and social media. We implemented a system comprising: a vector database integrating academic papers, government sources, news media, and social media; a Retrieval-Augmented Generation chatbot using ReAct agent architecture with multi-tool orchestration across five knowledge sources; and an automated report generation system with modules for news analysis, research synthesis, social media sentiment analysis, and user interaction pattern identification. Performance was assessed using a 0-5 scoring scale. For single-turn evaluation, the chatbot achieved mean scores of 4.83 for relevance, 4.89 for routing, 4.50 for reference quality, 4.90 for correctness, and 4.88 for professional identity (overall 4.80). Multi-turn evaluation yielded higher scores: context retention 4.94, topic coherence 5.00, and overall 4.98. The report generation system achieved completeness 4.00-5.00, correctness 4.00-5.00, and helpfulness 3.67-5.00, with reference validity 5.00 across all periods. This study demonstrates the feasibility of an integrated AI agent system for bidirectional HPV vaccine communication. The architecture enables verified information delivery with source attribution while providing systematic public discourse analysis, with a transferable framework for adaptation to other medical contexts.